Discordance between commercial genotyping platforms for APOE polymorphisms in Libyan patients with coronary heart disease: a methodological pilot study
Commercial APOE genotyping platforms are widely used in cardiovascular genetic studies, but their performance in genetically understudied populations is rarely verified. This pilot study compared a reverse-hybridization strip assay and a real-time PCR (qPCR) kit for APOE genotyping (rs429358 and rs7412) in Libyan participants and examined how their calls disagreed. In a validation subset of 28 individuals, the strip assay gave no valid result in 5 (17.9%). Among the 23 samples valid on both platforms, genotype concordance was 8/23 (34.8%; 95% CI 18.8–55.1%) and Cohen’s κ was 0.19 (slight agreement). Single-SNP agreement was 65.2% for rs429358 and 60.9% for rs7412. The strip assay consistently reported more minor alleles than qPCR, but without a sequencing reference standard it is unknown which platform is correct. APOE genotype frequencies in Libyan patients with coronary heart disease could therefore not be reliably determined; strip-derived calls for 60 patients are provided only as unverified, exploratory data (Additional file 1). Sequencing confirmation should precede any larger APOE association study in this population.
Authors
- Mohamed Nouri El-Attug
- Emhamed A Boras
- Salem Hasn Abukres (ORCID: https://orcid.org/0009-0007-5598-7112)
- Samya M Khaled
- Abdulrazag F. Ahmed (ORCID: https://orcid.org/0009-0004-1658-8993)
- Khaled H. Alzrigan
Institutions
- University of Tripoli (LY)
- Alasmarya Islamic University (LY)
- University Elmergib (LY)
- Libyan Academy (LY)
Publication Details
- Journal
- BMC Research Notes
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s13104-026-08134-5
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00